Administration of eribulin with a dose of 1.4 mg/m2 for days1 and 8. Administration of trastuzumab every 3 weeks with a starting dose of 8 mg/kg followed by 6 mg/kg as the second and subsequent doses.
Sponsors
Kurume University School of Medicine Department of Surgery, The University of Tokushima graduate school
Conditions
Breast cancerHER2 positive metastatic breast cancer
Phase 2
Prospective study of Eribulin plus Trastuzumab in patients with HER-2 positive metastatic breast cancer (KSCOG-BC06)
Active, not recruitingJPRN-UMIN000010761
Start: 2013-02-01Target: 30Updated: 2026-06-29
Phase II trial with eribulin and trastuzumab for advanced/recurrent HER2-positive breast cancer
Active, not recruitingJPRN-UMIN000010844
Start: 2013-06-15Target: 30Updated: 2026-06-29